Breast Cancer | Specialty

ATEMPT Trial at Dana-Farber Cancer Institute

October 1st 2014

BRCA Screening Recommendations by Geneticist Mary-Claire King

October 1st 2014

Latest News & Insight: October 1, 2014

October 1st 2014

CLEOPATRA Trial Update Shows Dramatic OS Benefit

September 28th 2014

Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median OS by almost 16 months over standard first-line therapy.

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study

September 28th 2014

Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Targeting Mitosis: First Polo-Like Kinase Inhibitor Moves Closer to FDA Approval

September 25th 2014

The concept of targeting mitotic cell division to halt the progression of rapidly dividing cancer cells has long been a staple of oncology therapy, yet chemotherapy agents that are the prime examples of this approach are nonselective in their action and can kill normal and malignant cells alike.

Bevacizumab Improves Survival in Metastatic Breast Cancer

September 25th 2014

Treatment with the combination of bevacizumab and chemotherapy improved PFS and OS in women with HER2-negative metastatic breast cancer.

Dr. Mehta Discusses the Reliability of Automated Segmentation for Lung Volumes in Multiple Cancers

September 23rd 2014

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Multiple Factors Impact BRCA Testing Decision

September 23rd 2014

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

Most Breast Cancer Patients Forgo Reconstruction Surgery Without Regret

September 22nd 2014

Although universal insurance coverage for postmastectomy breast reconstruction has been mandated since 1998, a new study has found that the persistently high rates of American women who choose not to undergo reconstruction surgery are due primarily to patient preferences and not a lack of awareness.

Dr. Attai Discusses 5-Year Outcomes for APBI With Strut-Based Brachytherapy

September 17th 2014

Deanna J. Attai, MD, discusses a 5-year follow up of patients receiving accelerated partial breast irradiation (APBI) using strut-based applicators.

Pertuzumab Use Continues to Expand in Breast Cancer

September 17th 2014

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

CDK 4/6, PI3K Inhibitor Combinations Explored in Breast Cancer

September 11th 2014

The combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer.

Oncologist Data from a New Survey Addresses the Emotional Impact of Treating Advanced Breast Cancer

September 10th 2014

Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.

Hurvitz Discusses PIK3CA Mutations, pCR, CDK4/6 Inhibitors, and Immunotherapies in Breast Cancer

September 9th 2014

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

Dr. Gralow on the Use of Bisphosphonates in Early-Stage Breast Cancer

September 9th 2014

Julie R. Gralow, MD, discusses the use of bisphosphonates in early-stage breast cancer.

Dr. Chan on Improving Mammography Screening Rates With Signed Letters

September 8th 2014

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer

September 7th 2014

The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.

Novel Peptide Vaccine Safe, Effective in High-Risk Breast Cancer

September 6th 2014

A novel HER2-derived peptide vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in the adjuvant setting.

Veliparib Active in Patients with BRCA-Positive Breast, Ovarian Tumors

September 6th 2014

The PARP inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.